Edwards Lifesciences Corporation EW

Revenue Intelligence Report • 69 quarters of SEC filing data • Updated 2026-10-14 • Data through 2026-06-30

Edwards Lifesciences Corporation's latest quarterly revenue is $1.7B for the period ending 2026-06-30. The model projects $7.8B across the next four quarters (+20.5% versus the preceding four quarters). The forecast uses SG&A data; model selection and estimation exclude the latest quarter, whose retrospective holdout error is 5.0%. These are statistical associations, not estimates of the causal effect of spending.

Investment Thesis

The GAM forecast is based on reported revenue and SG&A data through 2026-06-30. Training MAPE measures fit to historical data; the separately reported holdout error measures a withheld quarter. Spending coefficients describe associations and do not establish causation.

Next 4 Quarters
$7.85B
+20.5% YoY
R&D Multiplier
$1.57 per $1
SG&A Multiplier
$3.91 per $1
Training Fit
3.6% MAPE
Retrospective holdout (Q2 FY2026): The model predicted $1.83B vs the actual $1.74B — an error of 5.0%.
Retrospective one-quarter holdout: model fitting and selection exclude this quarter. Historical inputs use the latest available restatements, so this is not a preserved real-time forecast.

Revenue Forecast

EW Revenue Forecast

Quarterly Detail

QuarterModel ForecastActual95% RangeYoY GrowthStatus
Q2 FY2026
Period end 2026-06-30		 $1.83B $1.74B $1.61B–$2.07B +19.3% ✓ In range
Q3 FY2026
Period end 2026-09-30		 $1.92B $1.67B–$2.20B +23.4%
Q4 FY2026
Period end 2026-12-31		 $1.95B $1.65B–$2.30B +24.0%
Q1 FY2027
Period end 2027-03-31		 $1.81B $1.53B–$2.13B +9.5%
Q2 FY2027
Period end 2027-06-30		 $2.18B $1.81B–$2.61B +25.1%

Seasonal Factors

Multiplicative seasonal adjustment: These factors capture Edwards Lifesciences Corporation's systematic quarterly revenue patterns relative to the trend model. A factor of 1.05 means that quarter typically runs 5% above the underlying trend; 0.95 means 5% below. Factors are computed as the median of (actual / fitted) across all available quarters.
Fiscal QuarterSeasonal Factorvs TrendInterpretationObs.
FQ1 (Jan–Mar) 1.0214 +2.1% In line with trend 17
FQ2 (Apr–Jun) 1.0044 +0.4% In line with trend 17
FQ3 (Jul–Sep) 0.9733 -2.7% In line with trend 17
FQ4 (Oct–Dec) 1.0059 +0.6% In line with trend 17

Spending and Revenue

EW Spending Timing
Reading this chart: Each line shows the cumulative revenue association per $1 of spending over subsequent quarters. These estimates describe historical associations and do not establish causation.

Time-Varying Spending Associations

Time-varying analysis: A penalized spline model (GAM) tracks the association between log spending and log revenue over 69 quarters. Its coefficients describe conditional historical associations, not causal returns on spending.
Current SG&A elasticity: 0.4478x • R&D elasticity: 1.4012x
The model-term chart shows relative absolute term magnitudes. Its percentages are not shares of revenue or causal contributions to growth.
Enhanced forecast: The time-varying model (GAM) was selected using training fit, before evaluating the withheld quarter. Its holdout error is 5.0%.

Want this analysis for your portfolio?

I build custom revenue intelligence reports for investors and companies using SEC filing data, econometric modeling, and AI-powered insights.

Get in Touch

Data sourced from SEC EDGAR XBRL filings. SEC source data. Forecast model: GAM; spending associations: ARDL (linear) with 69 quarters. This analysis is for informational purposes only and does not constitute investment advice.

More in Healthcare

IQV GEHC RMD TECH AMGN ALGN GILD BSX